Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $8.00 price target on the stock.
LowReport
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $8.00 price target on the stock.
Vor Biopharma Inc. (NYSE: VOR) had its price target lowered by analysts at HC Wainwright from $17.50 to $13.00. They now have a "buy" rating on the stock.
MediumReport
Vor Biopharma Inc. (NYSE: VOR) had its price target lowered by analysts at HC Wainwright from $17.50 to $13.00. They now have a "buy" rating on the stock.
Vor Biopharma Inc. (NYSE: VOR) had its price target lowered by analysts at Stifel Nicolaus from $12.00 to $5.00. They now have a "buy" rating on the stock.
MediumReport
Vor Biopharma Inc. (NYSE: VOR) had its price target lowered by analysts at Stifel Nicolaus from $12.00 to $5.00. They now have a "buy" rating on the stock.
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials [Yahoo! Finance]
LowReport
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials [Yahoo! Finance]
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: